Lymphangiogenesis factors: A target for therapy?

Blood

Volumn 113, Issue 18, 2009, Pages 4135-4136

  Griffioen, Arjan W ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; OXYGEN; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN D; VASCULOTROPIN D ANTIBODY; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD VESSEL PERMEABILITY; BREAST ADENOCARCINOMA; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CAPILLARY DENSITY; CARCINOGENESIS; CLONAL ANERGY; COLLAPSE; DRUG TARGETING; ENDOTHELIUM CELL; EXPRESSION VECTOR; GENOME; HEALING; IMMUNOSURVEILLANCE; ISCHEMIA; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; LYMPHEDEMA; METASTASIS; METASTASIS INHIBITION; NEOPLASM; NONHUMAN; NOTE; OOCYTE; OXYGEN SUPPLY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 70449344401     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-198879     Document Type: Note

References (8)

1. Orlandini M, Marconcini L, Ferruzzi R, et al. Identifi- cation of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad SciUSA. 1996;93:11675-11680. (Pubitemid 26347181)
2. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factorD(VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad SciUSA. 1998;95:548-553. (Pubitemid 28083780)
3. Kärkkäinen A-M, Kotimaa A, Huusko J, et al. Vascular endothelial growth factor-D transgenic mice show enhanced blood capillary density, improved postischemic muscle regeneration, and increased susceptibility to tumor formation. Blood. 2009;113:4468-4475.
4. Baldwin ME, Halford MM, Roufail S, et al. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol. 2005;25:2441-2449. (Pubitemid 40354637)
5. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7:186-191. (Pubitemid 32148485)
6. Kubo H, Fujiwara T, Jussila L, et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood. 2000;96:546-553. (Pubitemid 30463374)
7. Bouma-ter Steege JC, Baeten CI, Thijssen VL, et al. Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin Cancer Res. 2004;10:7171-7178.
8. Griffioen AW. Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level? Trends Cardiovasc Med. 2007;17:171-176.